News

Poorer motor control associates with greater cognitive difficulties in people with Friedreich’s ataxia (FA), a study from Belgium suggests. Its researchers also indicate that a recently validated cognitive test, although for a separate disease, ably captures the severity of problems with higher-level thinking in these patients, and could be used in…

The CRISPR-Cas9 gene editing technique safely removed the gene expansion that causes Friedrich’s ataxia (FA), allowing for normal frataxin levels and more functional mitochondria in cells taken from patients, an early study reported. This work, and further experiments in mice, supports the potential of a stem cell approach to treating…

Neurofilament light chain may be a new blood biomarker to monitor disease severity and response to treatment among people with Friedreich’s ataxia (FA), particularly younger ones, a study suggests. The study, “Neurofilament light chain as a potential biomarker of disease status in Friedreich ataxia,” was published…

Chondrial Therapeutics has merged with Zafgen, giving rise to Larimar Therapeutics, which will continue working to advance CTI-1601 as a possible frataxin replacement therapy for Friedrich’s ataxia (FA). Larimar’s arrival came about five months after Zafgen and Chondrial announced they had entered into a merger agreement. “We…

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for a disease that few people — sometimes even physicians — have heard of is challenging on its own merit.

Children younger than age 8 with symptoms of Friedreich’s ataxia are at a higher risk of faster disease progression and earlier loss of walking abilities, a single-center natural history study in Belgium reported. The findings were consistent with previous results from another natural history study, and may help to guide treatment…

While the ongoing COVID-19 pandemic won’t have much of an impact on cash available for new biotech startups, it has begun to cause delays in the development of gene therapies to treat a variety of rare diseases. That’s the consensus of industry experts who spoke in a May 26 webinar…